Shopping Cart
- Remove All
- Your shopping cart is currently empty
Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent inhibitor of complement component 5 (C5) with applications in studying immune-mediated necrotising myopathy (IMNM) [1] [2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent inhibitor of complement component 5 (C5) with applications in studying immune-mediated necrotising myopathy (IMNM) [1] [2]. |
In vitro | Zilucoplan (RA101495; 1-1000 nM; 30 min) suppresses the lipopolysaccharide-induced increase in C5a plasma levels in human whole blood, with an IC50 of 474.5 pM, and achieves a 65.7% reduction at 1 nM [2]. It binds to complement component 5 (C5), inhibiting its cleavage into C5a and C5b and preventing C5b's interaction with C6, thereby obstructing the formation of the membrane attack complex (MAC; C5b-9) and subsequent cell lysis [1]. |
In vivo | Zilucoplan (RA101495; 10 mg/kg; S.C.; daily for 6 days) effectively inhibits the onset of immune-mediated necrotising myopathy (IMNM) in C5-deficient mice treated with human complement and provides protection against myopathy in C57BL/6 mice [1]. |
Alias | RA101495 TFA |
Molecular Weight | 3562.18 (free base) |
Formula | (C2H4O)nC126H186N24O32.C2HF3O2 |
Storage | keep away from moisture | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.